SAGE Journals Online
Advertisement
Sign In to gain access to subscriptions and/or personal tools.

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Advertisement

Sign In to gain access to subscriptions and/or personal tools.
Journal of Psychopharmacology
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
0269881107081510v1
22/5/473    most recent
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Web of Science (3)
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Taylor, M.
Right arrow Articles by Evans, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Taylor, M.
Right arrow Articles by Evans, J.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Differential effects of citalopram and reboxetine on cortical Glx measured with proton MR spectroscopy

M. Taylor

University Department of Psychiatry, Warneford Hospital, Oxford, UK

SE Murphy

University Department of Psychiatry, Warneford Hospital, Oxford, UK

S. Selvaraj

University Department of Psychiatry, Warneford Hospital, Oxford, UK

M. Wylezinkska

The Centre for Functional Magnetic Resonance Imaging of the Brain, John Radcliffe Hospital, Oxford, UK

P. Jezzard

The Centre for Functional Magnetic Resonance Imaging of the Brain, John Radcliffe Hospital, Oxford, UK

PJ Cowen

University Department of Psychiatry, Warneford Hospital, Oxford,UK, phil.cowen{at}psych.ox.ac.uk

J. Evans

University Department of Psychiatry, Warneford Hospital, Oxford, UK, The Centre for Functional Magnetic Resonance Imaging of the Brain, John Radcliffe Hospital, Oxford, UK

The pharmacological effects of monoamine potentiating antidepressants are likely to be expressed ultimately on cortical pyramidal neurones that use glutamate as a neurotransmitter. However, there are few data on the effects of antidepressant treatment on cortical glutamate levels in humans. The aim of the present study was to use proton magnetic resonance spectroscopy (MRS) to assess the effects of short-term administration of the selective serotonin re-uptake inhibitor, citalopram and the selective noradrenaline re-uptake inhibitor, reboxetine, on a composite measure of glutamate and glutamine (Glx) in occipital cortex in healthy volunteers using a parallel group, placebo-controlled design. We found that relative both to placebo and reboxetine, seven days treatment with citalopram significantly increased cortical Glx. Our data suggest that short-term treatment with citalopram, but not reboxetine, increases occipital Glx in healthy subjects. Further studies are needed to find out if similar effects occur in anterior brain regions and whether they reflect changes in glutamate or glutamine or both.

This version was published on July 1, 2008

Journal of Psychopharmacology, Vol. 22, No. 5, 473-476 (2008)
DOI: 10.1177/0269881107081510
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?




Advertisement